The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis

Several long noncoding RNAs (lncRNAs) are abnormally expressed in prostate cancer (PCa), suggesting that they could serve as novel prognostic markers. The current meta-analysis was undertaken to better define the prognostic value of various lncRNAs in PCa. The PubMed, Embase, Medline, and Cochrane L...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2017-12, Vol.96 (51), p.e9279-e9279
Main Authors: Wu, Xian-Lan, Zhang, Ji-Wang, Li, Bai-Song, Peng, Shu-Sheng, Yuan, Yong-Qiang
Format: Article
Language:English
Subjects:
Aged
Disease-Free Survival
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Neoplasm Invasiveness - pathology
Neoplasm Staging
Prognosis
Prostatic Neoplasms - genetics
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Risk Assessment
RNA, Long Noncoding - genetics
Survival Analysis
Systematic Review and Meta-Analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2854-48610ff757bf95b97ecc8bf673ec694f0ca3ed6a64c4f80e3de0c29d1a8c1c6d3
container_end_page e9279
container_issue 51
container_start_page e9279
container_title Medicine (Baltimore)
container_volume 96
creator Wu, Xian-Lan
Zhang, Ji-Wang
Li, Bai-Song
Peng, Shu-Sheng
Yuan, Yong-Qiang
description Several long noncoding RNAs (lncRNAs) are abnormally expressed in prostate cancer (PCa), suggesting that they could serve as novel prognostic markers. The current meta-analysis was undertaken to better define the prognostic value of various lncRNAs in PCa. The PubMed, Embase, Medline, and Cochrane Library databases were systematically searched up to February 19, 2017, to retrieve eligible articles. Outcomes analyzed were biochemical recurrence-free survival (BRFS), overall survival (OS), metastasis-free survival (MFS), and prostate cancer-specific survival (PCSS). Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calculated using fixed-effects or random-effects models. A total of 10 studies, evaluating 11 PCa-related lncRNAs, were included in the meta-analysis. Pooled results indicate that the abnormal expression of candidate lncRNAs in PCa samples predicted poor BRFS (HR: 1.67, 95%CI: 1.37-2.04, P 
doi_str_mv 10.1097/MD.0000000000009279
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5758189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993997554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2854-48610ff757bf95b97ecc8bf673ec694f0ca3ed6a64c4f80e3de0c29d1a8c1c6d3</originalsourceid><addsrcrecordid>eNpdUcFu1DAQtRCIbgtfgIR85JJiO3Ycc0BatRSQ2iKhcrYmzqQbcOzFTnbZvyfbLVXpXEaaee_N6D1C3nB2ypnR76_OT9mjMkKbZ2TBVVkVylTyOVkwJlShjZZH5Djnn4zxUgv5khwJUxoma70g6WaFdJ3ibYh57B3dgJ-Qxo5CE2IawPsdxT_rhDljS31w36-XmfZhz8kj7CkOkutDHOADXdK8yyMOd_OEmx63FEJLBxyhgAB-l_v8irzowGd8fd9PyI-LTzdnX4rLb5-_ni0vCydqJQtZV5x1nVa66YxqjEbn6qardImuMrJjDkpsK6ikk13NsGyROWFaDrXjrmrLE_LxoLuemgFbh2FM4O069QOknY3Q2_83oV_Z27ixSqua12YWeHcvkOLvCfNohz479B4CxilbbmYbjVZKztDyAHWzLTlh93CGM7tPy16d26dpzay3jz984PyLZwbIA2Ab_Ygp__LTFpNdIfhxdaentBGFYFxzIQQr5omW5V_H2KNB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993997554</pqid></control><display><type>article</type><title>The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis</title><source>Open Access: PubMed Central</source><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><creator>Wu, Xian-Lan ; Zhang, Ji-Wang ; Li, Bai-Song ; Peng, Shu-Sheng ; Yuan, Yong-Qiang</creator><creatorcontrib>Wu, Xian-Lan ; Zhang, Ji-Wang ; Li, Bai-Song ; Peng, Shu-Sheng ; Yuan, Yong-Qiang</creatorcontrib><description>Several long noncoding RNAs (lncRNAs) are abnormally expressed in prostate cancer (PCa), suggesting that they could serve as novel prognostic markers. The current meta-analysis was undertaken to better define the prognostic value of various lncRNAs in PCa. The PubMed, Embase, Medline, and Cochrane Library databases were systematically searched up to February 19, 2017, to retrieve eligible articles. Outcomes analyzed were biochemical recurrence-free survival (BRFS), overall survival (OS), metastasis-free survival (MFS), and prostate cancer-specific survival (PCSS). Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calculated using fixed-effects or random-effects models. A total of 10 studies, evaluating 11 PCa-related lncRNAs, were included in the meta-analysis. Pooled results indicate that the abnormal expression of candidate lncRNAs in PCa samples predicted poor BRFS (HR: 1.67, 95%CI: 1.37-2.04, P &lt; .05), without significant heterogeneity among studies (I = 44%, P = .06). Low PCAT14 expression was negatively associated with OS (HR: 0.66, 95%CI: 0.54-0.79, P &lt; .05), MFS (HR: 0.59, 95%CI: 0.48-0.72, P &lt; .05), and PCSS (HR: 0.50, 95%CI: 0.38-0.66, P &lt; .05). Again, there was no significant heterogeneity among studies. The robustness of our results was confirmed by sensitivity and publication bias analyses. We conclude that expression analysis of selected lncRNAs may be of prognostic value in PCa patients.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000009279</identifier><identifier>PMID: 29390487</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Aged ; Disease-Free Survival ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness - pathology ; Neoplasm Staging ; Prognosis ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Risk Assessment ; RNA, Long Noncoding - genetics ; Survival Analysis ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2017-12, Vol.96 (51), p.e9279-e9279</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2854-48610ff757bf95b97ecc8bf673ec694f0ca3ed6a64c4f80e3de0c29d1a8c1c6d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758189/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758189/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29390487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Xian-Lan</creatorcontrib><creatorcontrib>Zhang, Ji-Wang</creatorcontrib><creatorcontrib>Li, Bai-Song</creatorcontrib><creatorcontrib>Peng, Shu-Sheng</creatorcontrib><creatorcontrib>Yuan, Yong-Qiang</creatorcontrib><title>The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Several long noncoding RNAs (lncRNAs) are abnormally expressed in prostate cancer (PCa), suggesting that they could serve as novel prognostic markers. The current meta-analysis was undertaken to better define the prognostic value of various lncRNAs in PCa. The PubMed, Embase, Medline, and Cochrane Library databases were systematically searched up to February 19, 2017, to retrieve eligible articles. Outcomes analyzed were biochemical recurrence-free survival (BRFS), overall survival (OS), metastasis-free survival (MFS), and prostate cancer-specific survival (PCSS). Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calculated using fixed-effects or random-effects models. A total of 10 studies, evaluating 11 PCa-related lncRNAs, were included in the meta-analysis. Pooled results indicate that the abnormal expression of candidate lncRNAs in PCa samples predicted poor BRFS (HR: 1.67, 95%CI: 1.37-2.04, P &lt; .05), without significant heterogeneity among studies (I = 44%, P = .06). Low PCAT14 expression was negatively associated with OS (HR: 0.66, 95%CI: 0.54-0.79, P &lt; .05), MFS (HR: 0.59, 95%CI: 0.48-0.72, P &lt; .05), and PCSS (HR: 0.50, 95%CI: 0.38-0.66, P &lt; .05). Again, there was no significant heterogeneity among studies. The robustness of our results was confirmed by sensitivity and publication bias analyses. We conclude that expression analysis of selected lncRNAs may be of prognostic value in PCa patients.</description><subject>Aged</subject><subject>Disease-Free Survival</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Risk Assessment</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Survival Analysis</subject><subject>Systematic Review and Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdUcFu1DAQtRCIbgtfgIR85JJiO3Ycc0BatRSQ2iKhcrYmzqQbcOzFTnbZvyfbLVXpXEaaee_N6D1C3nB2ypnR76_OT9mjMkKbZ2TBVVkVylTyOVkwJlShjZZH5Djnn4zxUgv5khwJUxoma70g6WaFdJ3ibYh57B3dgJ-Qxo5CE2IawPsdxT_rhDljS31w36-XmfZhz8kj7CkOkutDHOADXdK8yyMOd_OEmx63FEJLBxyhgAB-l_v8irzowGd8fd9PyI-LTzdnX4rLb5-_ni0vCydqJQtZV5x1nVa66YxqjEbn6qardImuMrJjDkpsK6ikk13NsGyROWFaDrXjrmrLE_LxoLuemgFbh2FM4O069QOknY3Q2_83oV_Z27ixSqua12YWeHcvkOLvCfNohz479B4CxilbbmYbjVZKztDyAHWzLTlh93CGM7tPy16d26dpzay3jz984PyLZwbIA2Ab_Ygp__LTFpNdIfhxdaentBGFYFxzIQQr5omW5V_H2KNB</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Wu, Xian-Lan</creator><creator>Zhang, Ji-Wang</creator><creator>Li, Bai-Song</creator><creator>Peng, Shu-Sheng</creator><creator>Yuan, Yong-Qiang</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171201</creationdate><title>The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis</title><author>Wu, Xian-Lan ; Zhang, Ji-Wang ; Li, Bai-Song ; Peng, Shu-Sheng ; Yuan, Yong-Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2854-48610ff757bf95b97ecc8bf673ec694f0ca3ed6a64c4f80e3de0c29d1a8c1c6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Disease-Free Survival</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Risk Assessment</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Survival Analysis</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Xian-Lan</creatorcontrib><creatorcontrib>Zhang, Ji-Wang</creatorcontrib><creatorcontrib>Li, Bai-Song</creatorcontrib><creatorcontrib>Peng, Shu-Sheng</creatorcontrib><creatorcontrib>Yuan, Yong-Qiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Xian-Lan</au><au>Zhang, Ji-Wang</au><au>Li, Bai-Song</au><au>Peng, Shu-Sheng</au><au>Yuan, Yong-Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>96</volume><issue>51</issue><spage>e9279</spage><epage>e9279</epage><pages>e9279-e9279</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Several long noncoding RNAs (lncRNAs) are abnormally expressed in prostate cancer (PCa), suggesting that they could serve as novel prognostic markers. The current meta-analysis was undertaken to better define the prognostic value of various lncRNAs in PCa. The PubMed, Embase, Medline, and Cochrane Library databases were systematically searched up to February 19, 2017, to retrieve eligible articles. Outcomes analyzed were biochemical recurrence-free survival (BRFS), overall survival (OS), metastasis-free survival (MFS), and prostate cancer-specific survival (PCSS). Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calculated using fixed-effects or random-effects models. A total of 10 studies, evaluating 11 PCa-related lncRNAs, were included in the meta-analysis. Pooled results indicate that the abnormal expression of candidate lncRNAs in PCa samples predicted poor BRFS (HR: 1.67, 95%CI: 1.37-2.04, P &lt; .05), without significant heterogeneity among studies (I = 44%, P = .06). Low PCAT14 expression was negatively associated with OS (HR: 0.66, 95%CI: 0.54-0.79, P &lt; .05), MFS (HR: 0.59, 95%CI: 0.48-0.72, P &lt; .05), and PCSS (HR: 0.50, 95%CI: 0.38-0.66, P &lt; .05). Again, there was no significant heterogeneity among studies. The robustness of our results was confirmed by sensitivity and publication bias analyses. We conclude that expression analysis of selected lncRNAs may be of prognostic value in PCa patients.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>29390487</pmid><doi>10.1097/MD.0000000000009279</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2017-12, Vol.96 (51), p.e9279-e9279
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5758189
source Open Access: PubMed Central; HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals
subjects Aged
Disease-Free Survival
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Neoplasm Invasiveness - pathology
Neoplasm Staging
Prognosis
Prostatic Neoplasms - genetics
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Risk Assessment
RNA, Long Noncoding - genetics
Survival Analysis
Systematic Review and Meta-Analysis
title The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A53%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prognostic%20value%20of%20abnormally%20expressed%20lncRNAs%20in%20prostatic%20carcinoma:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Wu,%20Xian-Lan&rft.date=2017-12-01&rft.volume=96&rft.issue=51&rft.spage=e9279&rft.epage=e9279&rft.pages=e9279-e9279&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000009279&rft_dat=%3Cproquest_pubme%3E1993997554%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2854-48610ff757bf95b97ecc8bf673ec694f0ca3ed6a64c4f80e3de0c29d1a8c1c6d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1993997554&rft_id=info:pmid/29390487&rfr_iscdi=true